Research ExplorerPublicationsUnilateral prostate cancer cannot be accurately predicted in...

Unilateral prostate cancer cannot be accurately predicted in low-risk patients.

Standard

Unilateral prostate cancer cannot be accurately predicted in low-risk patients. / Isbarn, Hendrik; Karakiewicz, Pierre I; Vogel, Susanne; Jeldres, Claudio; Lughezzani, Giovanni; Briganti, Alberto; Montorsi, Francesco; Perrotte, Paul; Ahyai, Sascha A; Budäus, Lars; Eichelberg, Christian; Heuer, Roman; Köllermann, Jens; Sauter, Guido; Schlomm, Thorsten; Steuber, Thomas; Haese, Alexander; Zacharias, Mario; Fisch, Margit; Heinzer, Hans; Huland, Hartwig; Chun, Felix; Graefen, Markus.

In: INT J RADIAT ONCOL, 2009.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Isbarn, H, Karakiewicz, PI, Vogel, S, Jeldres, C, Lughezzani, G, Briganti, A, Montorsi, F, Perrotte, P, Ahyai, SA, Budäus, L, Eichelberg, C, Heuer, R, Köllermann, J, Sauter, G, Schlomm, T, Steuber, T, Haese, A, Zacharias, M, Fisch, M, Heinzer, H, Huland, H, Chun, F & Graefen, M 2009, 'Unilateral prostate cancer cannot be accurately predicted in low-risk patients.', INT J RADIAT ONCOL. <http://www.ncbi.nlm.nih.gov/pubmed/19864083?dopt=Citation>

APA

Isbarn, H., Karakiewicz, P. I., Vogel, S., Jeldres, C., Lughezzani, G., Briganti, A., Montorsi, F., Perrotte, P., Ahyai, S. A., Budäus, L., Eichelberg, C., Heuer, R., Köllermann, J., Sauter, G., Schlomm, T., Steuber, T., Haese, A., Zacharias, M., Fisch, M., ... Graefen, M. (2009). Unilateral prostate cancer cannot be accurately predicted in low-risk patients. INT J RADIAT ONCOL. http://www.ncbi.nlm.nih.gov/pubmed/19864083?dopt=Citation

Vancouver

Isbarn H, Karakiewicz PI, Vogel S, Jeldres C, Lughezzani G, Briganti A et al. Unilateral prostate cancer cannot be accurately predicted in low-risk patients. INT J RADIAT ONCOL. 2009.

Bibtex

@article{96cb2f9c2d5b457d980cc842df721606,
title = "Unilateral prostate cancer cannot be accurately predicted in low-risk patients.",
abstract = "PURPOSE: Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. We tested the accuracy of unilaterally unremarkable biopsy findings in cases of low-risk PCa patients who are potential candidates for HAT. METHODS AND MATERIALS: The study population consisted of 243 men with clinical stage",
author = "Hendrik Isbarn and Karakiewicz, {Pierre I} and Susanne Vogel and Claudio Jeldres and Giovanni Lughezzani and Alberto Briganti and Francesco Montorsi and Paul Perrotte and Ahyai, {Sascha A} and Lars Bud{\"a}us and Christian Eichelberg and Roman Heuer and Jens K{\"o}llermann and Guido Sauter and Thorsten Schlomm and Thomas Steuber and Alexander Haese and Mario Zacharias and Margit Fisch and Hans Heinzer and Hartwig Huland and Felix Chun and Markus Graefen",
year = "2009",
language = "Deutsch",
journal = "INT J RADIAT ONCOL",
issn = "0360-3016",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Unilateral prostate cancer cannot be accurately predicted in low-risk patients.

AU - Isbarn, Hendrik

AU - Karakiewicz, Pierre I

AU - Vogel, Susanne

AU - Jeldres, Claudio

AU - Lughezzani, Giovanni

AU - Briganti, Alberto

AU - Montorsi, Francesco

AU - Perrotte, Paul

AU - Ahyai, Sascha A

AU - Budäus, Lars

AU - Eichelberg, Christian

AU - Heuer, Roman

AU - Köllermann, Jens

AU - Sauter, Guido

AU - Schlomm, Thorsten

AU - Steuber, Thomas

AU - Haese, Alexander

AU - Zacharias, Mario

AU - Fisch, Margit

AU - Heinzer, Hans

AU - Huland, Hartwig

AU - Chun, Felix

AU - Graefen, Markus

PY - 2009

Y1 - 2009

N2 - PURPOSE: Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. We tested the accuracy of unilaterally unremarkable biopsy findings in cases of low-risk PCa patients who are potential candidates for HAT. METHODS AND MATERIALS: The study population consisted of 243 men with clinical stage

AB - PURPOSE: Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. We tested the accuracy of unilaterally unremarkable biopsy findings in cases of low-risk PCa patients who are potential candidates for HAT. METHODS AND MATERIALS: The study population consisted of 243 men with clinical stage

M3 - SCORING: Zeitschriftenaufsatz

JO - INT J RADIAT ONCOL

JF - INT J RADIAT ONCOL

SN - 0360-3016

ER -